Exploring the influence of microbiota on gestational diabetes and its potential as a biomarker

Abstract

Gestational diabetes mellitus (GDM) represents a significant health concern during pregnancy, impacting both maternal and fetal well-being. While conventional diagnostic protocols typically rely on blood glucose levels in the latter stages of pregnancy, there is a pressing need for early detection methods to mitigate potential risks. A plethora of glucose-based or non-glucose-based biomarkers have been investigated for their potential to predict GDM in early pregnancy. Though specific biomarkers showed promise in predicting GDM, their clinical usage has been constrained by the lack of validation and limitation in translating them into routine clinical use. This review aims to highlight and discuss the potential and practical utility of existing biomarkers and emergent biomarkers, such as microbiomes, in diagnosing GDM. A comprehensive analysis of recent studies reveals significant alterations in the composition and diversity of microbiota among women with GDM, suggesting their potential utility as predictive markers for this condition. For instance, distinct microbial profiles characterized by an increased abundance of Eisenbergiella, Tyzzerella 4, and Lachnospiraceae NK4A136, alongside decreased levels of Parabacteroides, Parasutterella, and Ruminococcaceae UCG 002, correlated with fasting blood glucose levels, hinting at their relevance in early GDM detection. Furthermore, proposed microbiota-targeted panels demonstrated promising predictive accuracy. Beyond gut microbiota, recent investigations have also explored the potential of oral microbiota as predictive biomarkers for GDM. Studies have highlighted the discriminatory capacity of specific oral microbes, such as Streptococcus in saliva and Leptotrichia in dental plaque, in distinguishing GDM from healthy pregnancies. Moreover, the examination of gut microbiota-derived metabolites has shown promising results in serum-based GDM prediction. These findings collectively underscore the potential of microbiota and its metabolites as valuable biomarkers for the early detection of GDM. However, further research is warranted to elucidate the mechanistic links between microbial dysbiosis and GDM pathogenesis, ultimately facilitating the development of targeted therapeutic interventions and personalized management strategies.